Bloomberg Anywhere Remote Login Bloomberg Terminal Request a Demo

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last 627.60
Change Today 0.00 / 0.00%
Volume 0.0
BLRX On Other Exchanges
Symbol
Exchange
OTC US
NASDAQ CM
Stuttgart
Tel Aviv
As of 10:24 AM 09/3/15 All times are local (Market data is delayed by at least 15 minutes).

biolinerx ltd (BLRX) Snapshot

Open
$621.00
Previous Close
$592.50
Day High
$630.00
Day Low
$611.00
52 Week High
03/4/15 - $1,059
52 Week Low
12/3/14 - $468.00
Market Cap
343.0M
Average Volume 10 Days
100.0K
EPS TTM
--
Shares Outstanding
54.6M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for BIOLINERX LTD (BLRX)

biolinerx ltd (BLRX) Related Businessweek News

No Related Businessweek News Found

biolinerx ltd (BLRX) Details

BioLineRx Ltd., a clinical stage biopharmaceutical development company, engages in identifying, in-licensing, and developing therapeutic candidates that address unmet medical needs. The company’s development pipeline consists of clinical-stage therapeutic candidates, including BL-1040, a novel polymer solution for use in the prevention of ventricular remodeling following an acute myocardial infarction; BL-8040, a novel peptide for the treatment of acute myeloid leukemia, stem cell mobilization, and other hematological indications; BL-7010, a novel polymer for the treatment of celiac disease; BL-5010, a medical device for the non-surgical removal of benign skin lesions; BL-7040, an oligonucleotide for the treatment of inflammatory bowel disease; and BL-8020, an orally available treatment for the hepatitis C virus and other viral indications. It also has four therapeutic candidates in the preclinical stages of development, including BL-8030 for the treatment of Hepatitis C; BL-9010 to treat severe allergies and asthma; BL-9020 for the treatment of type 1 diabetes; and BL-1110 for the treatment of neuropathic pain and scleroderma. The company has strategic collaboration with Novartis Pharma AG for the co-development of drug candidates. BioLineRx Ltd. was founded in 2003 and is headquartered in Jerusalem, Israel.

46 Employees
Last Reported Date: 03/23/15
Founded in 2003

biolinerx ltd (BLRX) Top Compensated Officers

Chief Executive Officer
Total Annual Compensation: $366.0K
Chief Financial & Operating Officer, Principa...
Total Annual Compensation: $269.0K
Vice President of Business Development
Total Annual Compensation: $241.0K
Vice President of Medical Affairs
Total Annual Compensation: $185.0K
Chief Scientific Officer
Total Annual Compensation: $215.0K
Compensation as of Fiscal Year 2014.

biolinerx ltd (BLRX) Key Developments

BioLineRx, Ltd. Announces Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2015

BioLineRx, Ltd. announced unaudited consolidated earnings results for the second quarter and six months ended June 30, 2015. The company’s operating loss for the three months ended June 30, 2015 amounted to $4.2 million, compared with an operating loss of $3.9 million for the corresponding 2014 period. Net financial income amounted to $0.2 million for the three months ended June 30, 2015, compared to net financial expense of $0.4 million for the corresponding 2014 period. The company’s net loss for the three months ended June 30, 2015 amounted to $4.8 million, compared with a net loss of $4.1 million for the corresponding 2014 period. Loss per basic and diluted share was at $0.12 against $0.09 reported last year. The company’s operating loss for the six months ended June 30, 2015 amounted to $8.5 million, compared with an operating loss of $8.0 million for the corresponding 2014 period. Net financial income amounted to $0.3 million for the six months ended June 30, 2015, compared to net financial expense of $0.2 million for the corresponding 2014 period. Net financial income (expenses) for the 2015 period primarily relates to investment income earned on bank deposits, as well as banking fees. The company’s net loss for the six months ended June 30, 2015 amounted to $9.1 million, compared with a net loss of $6.2 million for the corresponding 2014 period. Loss per basic and diluted share was at $0.20 against $0.19 reported last year. Net cash used in operating activities was $7.2 million for the six months ended June 30, 2015, compared to net cash used in operating activities of $7.7 million for the corresponding 2014 period. The $0.5 million decrease in net cash used in operating activities during the six-month period in 2015, compared to the six-month period in 2014, was primarily the result of an increase in trade payables and accruals. Purchase of property and equipment was at $88,000 against $1,586,000 reported last year. Purchase of intangible assets was at $3,000 against $7,000 reported last year.

BioLineRx Ltd. Announces Initiation of Phase 2b Trial for Novel AML Consolidation Treatment

BioLineRx Ltd. announced the initiation of a Phase 2b trial for BL-8040 as a novel consolidation treatment for acute myeloid leukemia. The Phase 2b study will examine BL-8040 as part of a second stage treatment, termed consolidation therapy, to improve outcomes for AML patients who have achieved remission after the standard initial treatment regimen, known as induction therapy. The consolidation therapy is aimed at eliminating the minimal residual disease left in the bone marrow after induction therapy that can lead to relapse. This study is the first of three clinical studies in additional indications for BL-8040 which BioLineRx plans to commence during 2015, thus significantly expanding its unique BL-8040 oncology platform. Patients with AML relapse have a poor prognosis despite further therapy, and less than 10% of these patients are cured by conventional therapy. Leukemic stem cells that are dormant in the bone marrow are presumed to be a major reason for AML relapse. Based on the pre-clinical and clinical data accumulated to date, BL-8040 is anticipated to boost the efficacy of consolidation therapy due to its dual mechanism of action. Firstly, BL-8040 induces mobilization of leukemic cells from the bone marrow, which enhances the cytotoxic effects of chemotherapy, and secondly, it possesses anti-leukemic pro-apoptotic properties that help eliminate AML cells directly. The Phase 2b trial, which is conducted in collaboration with the University of Halle as sponsor and with the participation of two large leukemia study groups in Germany, is a double-blind, placebo-controlled, randomized, multi-center study aimed at assessing the efficacy of BL-8040 in addition to standard consolidation therapy in AML patients. The primary endpoint of the study is to compare the relapse free survival time in AML subjects in their first remission during a minimum follow-up time of 18 months after randomization. In addition, pharmacodynamic measurements will be conducted in order to assess the minimal residual disease, and biomarker analyses will be performed to identify predictors of BL-8040 response. The study will enroll up to 194 patients at up to 25 sites in Germany. AML patients between 18 and 75 years of age with documented first remission will be randomized in a 1:1 ratio to receive high dose Cytarabine, either with BL-8040 or with a matching placebo, as consolidation therapy.

BioLineRx, Ltd. to Report Q2, 2015 Results on Aug 20, 2015

BioLineRx, Ltd. announced that they will report Q2, 2015 results at 9:00 AM, Israel Standard Time on Aug 20, 2015

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
BLRX:IT 627.60 0.00

BLRX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for BLRX.
View Industry Companies
 

Industry Analysis

BLRX

Industry Average

Valuation BLRX Industry Range
Price/Earnings -- Not Meaningful
Price/Sales -- Not Meaningful
Price/Book -- Not Meaningful
Price/Cash Flow -- Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact BIOLINERX LTD, please visit www.biolinerx.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.